surpass cvot tirzepatide results An Observational Study of Cardiovascular Outcomes of vs Glucagon-Like Peptide-1 Receptor Agonists Diabetes Distilled: SURPASS-CVOT – Tirzepatide

Stem Cells 27(10):2614-2623, 2009

PlexusDx patients should contact their prescriber if hydration symptoms don't improve within 48 hours of increased water intake

Ozempic as an add-on to basal insulin and Ozempic 1 mg vs 2 mg Primary endpoint: change in A1C from baseline SUSTAIN 5: add-on basal insulin 1,10,11 In adult patients with type 2 diabetes on basal insulin metformin Mean change in A1C from baseline at Week 30 Mean baseline A1C: SUSTAIN FORTE: Ozempic 1 mg vs 2 mg 1,8 In patients with type 2 diabetes on metformin sulfonylurea Mean change in A1C from baseline at Week 40 Mean baseline A1C: Results for SUSTAIN 5 and SUSTAIN FORTE based on sensitivity analyses of retrieved dropout population

The FDA does not approve compounded medications

This category has almost nothing to do with willpower or caloric math